Men with hormone-sensitive, metastatic prostate cancer who received docetaxel chemotherapy at the start of standard androgen deprivation therapy (ADT) lived longer than patients who received ADT alone.
• The projected 3-year overall survival data were
o 69.0 percent for men randomized to ADT + docetaxel-based chemotherapy
o 52.5 percent for men randomized to receive ADT alone
• The projected 3-year overall survival data for the men with a high extent of metastatic disease as defined above were
o 63.4 percent for men randomized to ADT + docetaxel-based chemotherapy
o 43.9 percent for men randomized to receive ADT alone
• The study’s independent Data and Safety Monitoring Committee recommended that the study results be made public because this planned interim analysis showed prolongation in overall survival.
these data are going to have significant impact on the management of metastatic prostate cancer because they imply that men with a significant extent of metastatic disease will now start to get docetaxel-based chemotherapy much earlier in the course of their disease than previously.
----Courtesy of The "New" Prostate InfoLink.